Ausbiz Capital is now SureStone Capital. Same team, same ABN and AFS authorisations.

ASX Announcements / Mayne Pharma Group Limited (ASX:MYX)

All Mayne Pharma Group Limited (ASX:MYX) announcement summaries, newest first. Every summary is drawn only from the company's official ASX release.

November 2026

Mayne Pharma Group Limited (ASX:MYX)
OperationsPrice Sensitive

Mayne Pharma to Sell International Segment for $55.5m

Mayne Pharma has agreed to sell Mayne Pharma International to Evaris Pharma for $55.5 million cash, subject to ACCC approval, to focus on the United States.

Mayne Pharma Group Limited (ASX:MYX)

8:52 am

6 Nov 2026

October 2026

Mayne Pharma Group Limited (ASX:MYX)
ResultsPrice Sensitive

Mayne Pharma 1Q FY27 Underlying EBITDA Falls to $5.3M

Mayne Pharma reported unaudited 1Q FY27 revenue of $95.7 million and underlying EBITDA of $5.3 million, down 52%, as Dermatology sales fell on generic entry.

Mayne Pharma Group Limited (ASX:MYX)

8:49 am

26 Oct 2026

Mayne Pharma Group Limited (ASX:MYX)
OperationsPrice Sensitive

Mayne Pharma Settles IMVEXXY Patent Case With Teva USA

Mayne Pharma settled its US IMVEXXY patent litigation with Teva, agreeing generic entry from 2 September 2032 with no payment, subject to court approval.

Mayne Pharma Group Limited (ASX:MYX)

9:43 am

16 Oct 2026

July 2026

Mayne Pharma Group Limited (ASX:MYX)
ResultsPrice Sensitive

Mayne Pharma FY26 Revenue $383.7m, EBITDA Down 33%

Mayne Pharma posted unaudited FY26 revenue of $383.7 million, down 6%, with underlying EBITDA of $31.7 million, down 33%, and a 65% FY26 gross margin.

Mayne Pharma Group Limited (ASX:MYX)

9:29 am

31 Jul 2026

Copyright © 2026 SureStone Capital
MYX ASX Announcement Summaries | SureStone Capital